Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Methotrexate use in systemic vasculitis

C A Langford1, M C Sneller, G S Hoffman

  • 1Immunologic Diseases Section, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland.

Rheumatic Diseases Clinics of North America
|November 15, 1997
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Immunoglobulin (Ig)M antibodies to proteinase 3 in granulomatosis with polyangiitis and microscopic polyangiitis.

Clinical and experimental immunology·2017
Same author

Decline of cellular activation in non-B cells after rituximab treatment in hepatitis C-associated mixed cryoglobulinemia vasculitis.

Journal of viral hepatitis·2016
Same author

Establishing the Feasibility of Face Transplantation in Granulomatosis With Polyangiitis.

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons·2016
Same author

Giant cell arteritis: Commentary on recommendations of the French Study Group for Large Vessel Vasculitis (GEFA).

La Revue de medecine interne·2016
Same author

Outcomes of nonsevere relapses in antineutrophil cytoplasmic antibody-associated vasculitis treated with glucocorticoids.

Arthritis & rheumatology (Hoboken, N.J.)·2015
Same author

Rituximab for the treatment of relapses in antineutrophil cytoplasmic antibody-associated vasculitis.

Arthritis & rheumatology (Hoboken, N.J.)·2014
Same journal

Bridging the Divide in Global Rheumatology.

Rheumatic diseases clinics of North America·2026
Same journal

Foreword.

Rheumatic diseases clinics of North America·2026
Same journal

Pulmonary Complications of Biological Therapies in Inflammatory and Autoimmune Diseases.

Rheumatic diseases clinics of North America·2026
Same journal

Artificial Intelligence and Social Determinants of Health.

Rheumatic diseases clinics of North America·2026
Same journal

Updates in Ultrasound in Rheumatology.

Rheumatic diseases clinics of North America·2026
Same journal

Health Systems Strengthening to Promote Access to Care for Rheumatic and Musculoskeletal Diseases Globally.

Rheumatic diseases clinics of North America·2026
See all related articles

Glucocorticoids (GS) and cyclophosphamide (CYC) improve outcomes for systemic vasculitis but have risks. Methotrexate (MTX) shows promise as a less toxic alternative, though further research is needed for optimal use.

Area of Science:

  • Rheumatology
  • Immunology
  • Pharmacology

Background:

  • Systemic vasculitis treatment traditionally relies on glucocorticoids (GS) and cyclophosphamide (CYC).
  • These established therapies are associated with significant drug-induced morbidity and mortality.
  • Limitations include treatment resistance and potential for disease relapse, necessitating alternative treatments.

Purpose of the Study:

  • To evaluate the efficacy and safety of methotrexate (MTX) as a therapeutic alternative in systemic vasculitis.
  • To explore MTX's potential role in managing vasculitis, considering its toxicity profile compared to current standards.

Main Methods:

  • Review of initial results and clinical data regarding MTX use in systemic vasculitis patients.
  • Analysis of observed drug-related toxicities and disease relapse rates associated with MTX therapy.

Related Experiment Videos

Main Results:

  • Initial findings suggest MTX is a valuable addition to vasculitis treatment regimens.
  • While MTX-related toxicity and disease relapse can still occur, its profile appears manageable.
  • MTX demonstrates encouraging results in improving patient outcomes.

Conclusions:

  • Methotrexate (MTX) presents a promising, potentially less toxic therapeutic option for systemic vasculitis.
  • Further research is essential to establish optimal dosing and long-term safety of MTX in vasculitis management.
  • MTX may offer an improved risk-benefit profile for select patients with systemic vasculitis.